Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: a Review

Total Page:16

File Type:pdf, Size:1020Kb

Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: a Review International Journal of Molecular Sciences Review Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: A Review Rui Liu 1,2,3,4 , Jianming Cheng 1,2,3,* and Hao Wu 1,2,3,* 1 Jiangsu Key Laboratory of Research and Development in Marine Bio-resource Pharmaceutics, Nanjing University of Chinese Medicine, Nanjing 210023, China; [email protected] 2 Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing 210023, China 3 School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China 4 School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA * Correspondence: [email protected] (J.C.); [email protected] (H.W.); Tel.: +86-25-85811524 (J.C.); +86-25-85811206 (H.W.) Received: 21 December 2018; Accepted: 19 January 2019; Published: 22 January 2019 Abstract: Diabetes is a chronic metabolic disorder which leads to high blood sugar levels over a prolonged period. Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and results from the body’s ineffective use of insulin. Over ten dipeptidyl peptidase IV (DPP-IV) inhibitory drugs have been developed and marketed around the world in the past decade. However, owing to the reported adverse effects of the synthetic DPP-IV inhibitors, attempts have been made to find DPP-IV inhibitors from natural sources. Food-derived components, such as protein hydrolysates (peptides), have been suggested as potential DPP-IV inhibitors which can help manage blood glucose levels. This review focuses on the methods of discovery of food-derived DPP-IV inhibitory peptides, including fractionation and purification approaches, in silico analysis methods, in vivo studies, and the bioavailability of these food-derived peptides. Moreover, food-derived DPP-IV inhibitory peptides discovered during this decade are listed and distributed in a 3D scatter plot graph based on their IC50, molecular weight, and grand average of hydropathicity values, which can help us to understand the relationship between the features of the peptides and their activities. Keywords: dipeptidyl-peptidase IV inhibition; food proteins; peptides; type 2 diabetes mellitus 1. Introduction Diabetes is a chronic metabolic disorder which leads to high blood sugar levels over a prolonged period. Type 2 diabetes mellitus (T2DM), type 1 diabetes mellitus (T1DM), and gestational diabetes mellitus are the most frequent forms; other specific types exist that are much less common [1,2]. In recent years, diabetes has become one of the leading causes of death worldwide. According to the International Diabetes Federation (IDF), it is estimated that about 425 million people were living with diabetes globally in 2017 and that the number will be 642 million by 2040 [3]. T2DM is the most common form of diabetes and results from the body’s ineffective use of insulin: it accounts for the vast majority of people with diabetes around the world. The World Health Organization (WHO) estimates that 90 percent of people living with diabetes have type 2 disease [4]. The exact cause of T2DM remains unclear [5]. The involvement of insulin resistance and pancreatic β-cell dysfunction in the pathogenesis of T2DM has been discussed for a long time [6]. Kahn et al. determined the relationship between insulin sensitivity and β-cell function, and pointed out that the relationship was similar to a feedback loop control system [7]. After insulin-sensitive tissues, such as skeletal muscle, adipose tissue, and liver, Int. J. Mol. Sci. 2019, 20, 463; doi:10.3390/ijms20030463 www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2019, 20, 463 2 of 22 take up glucose, these tissues send a feedback signal to the β-cells that they need insulin. In order to maintain normal glucose homoeostasis, β-cells release a certain concentration of insulin. If insulin resistance occurs, the feedback signal from tissues causes the β-cells to increase insulin output to maintain normal glucose tolerance. However, under the situation of insulin resistance, and once the β-cells become unable to release sufficient insulin, glucose concentrations will increase [6]. Genetic and environmental factors are reported to be crucial determinants of insulin resistance and β-cell dysfunction. Genomic investigation has shown that more than 50 gene loci are associated with T2DM [8]. Environmental factors, including energy expenditure, caloric intake, nutrient composition, environmental chemicals, and even the gut environment and gut microbiome, are important as well [9,10]. Aside from those factors, the brain–gut axis also plays an important role in normal glucose homoeostasis. The gastrointestinal tract can release various peptides which are closely related to T2DM, such as glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 and GIP are well known as incretins and can increase insulin secretion and suppress glucagon secretion [11]. GLP-1 and GIP are released into the small intestine and regulate glucose homoeostasis. The incretin effect, defined as the insulin secretory response of the incretins, accounts for at least 50% of the total insulin secreted after a meal [12]. However, both GLP-1 and GIP are rapidly deactivated by an enzyme: dipeptidyl peptidase IV (DPP-IV). DPP-IV can cleave the N-terminal dipeptide residues of GLP-1 and GIP and produce inactive incretins, which leads to GLP-1 and GIP losing their insulinotropic activity [13,14]. DPP-IV is a homodimeric serine peptidase, which consists of approximately 700 amino acids in each subunit. DPP-IV preferentially cleaves substrate peptides with Pro or Ala at the penultimate position of peptides. DPP-IV is responsible for the degradation of GLP-1 and GIP [15]. DPP-IV inhibition is a key target in the treatment of T2DM, and DPP-IV inhibitors were one of the first classes of oral antidiabetic drugs to be prospectively designed as anti-hyperglycemic agents [16]. To date, more than ten DPP-IV inhibitory drugs, which are classified as gliptins, have been developed and marketed around the world [17]. In 2006 Sitagliptin was the first gliptin to be approved by the United States Food and Drug Administration [18], and new members continue to be approved, such as Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, Alogliptin, Trelagliptin, Omarigliptin, Evogliptin, and Gosogliptin [16]. However, these synthetic DPP-IV inhibitors are reported to have some adverse effects [19], such as gastrointestinal adverse effects [20], allergic reactions [21], skin-related side effects [22], and musculoskeletal disorders [23]. However, DPP-IV inhibitors have been discovered in foods, herbal preparations, natural sources, and traditional Chinese medicines, including phenolic compounds from blueberry–blackberry wine blends [24], alkaloids from seed extract of Castanospermum australe [25], and procyanidins from grape seed [26], all of which have shown good DPP-IV inhibitory activity. Various foods, including milk, fish, wheat gluten, beans, egg, and bivalve mollusks, are natural protein sources; after enzymatic hydrolysis, microbial fermentation, decoction, or some other physical and/or chemical processing, their proteins may be degraded and release various DPP-IV inhibitory peptides [27–32]. It has been reported different peptides showed different DPP-IV inhibitory modes, including competitive, uncompetitive, noncompetitive and mixed-type modes, which means those peptides might exert DPP-IV inhibitory activity by binding either at the active site and/or outside the catalytic site of DPP-IV [5]. It has been suggested that those natural food- or herb-derived constituents should be safer than synthetic forms, and could be used for glycemic management. Among the sources of DPP-IV inhibitors, food protein-derived DPP-IV inhibitory peptides have attracted the attention of more and more researchers, owing to their high efficacy and safety [33]. The purpose of this review is to describe the discovery of food-derived DPP-IV inhibitory peptides, and to provide information on their use in glycemic management and blood glucose regulation. Int. J. Mol. Sci. 2019, 20, 463 3 of 22 Int. J. Mol.2. Methods Sci. 2019, 20 for, 463 Discovering Food-Derived DPP-IV Inhibitory Peptides 3 of 23 2.1.Many Enzymatic bioactive Hydrolysates peptides have of Food been Proteins discovered in the enzymatic hydrolysates of various food proteins. ManyIn order bioactive to obtain peptides active have peptides, been discoveredproteins used in theas enzymaticprecursors hydrolysatesshould be subjected of various to food enzymaticproteins. hydrolysis In order by to single obtain or active multiple peptides, enzymes proteins under usedspecific as precursorsconditions should(temperature, be subjected pH, to enzyme-to-substrateenzymatic hydrolysis ratio, byhydrolysis single or time, multiple etc.) fo enzymesr each protease. under specific Highly conditions active peptides (temperature, can be pH, discoveredenzyme-to-substrate only in these optimized ratio, hydrolysis active enzymatic time, etc.) hydrolysates. for each protease. It is important Highly active to optimize peptides the can be hydrolysisdiscovered conditions only in of these various optimized proteases active becaus enzymatice protein hydrolysates. hydrolysates It are is important present at to the optimize very the beginninghydrolysis step of conditions the discovery of various
Recommended publications
  • Variations Through the Day of Hepatic and Muscular Cathepsin A
    Downloaded from Br. J. Nutr. (1980), 4,61 61 https://www.cambridge.org/core Variations through the day of hepatic and muscular cathepsin A (carboxypeptidase A; EC 3.4.12.2), C (dipeptidyl peptidase; EC 3.4.14.1) and D (endopeptidase D ;EC 3.4.23.5) activities and free amino acids of blood in rats: influence of feeding schedule . IP address: BY CHRISTIANE OBLED, M. ARNAL AND C. VALIN* 170.106.40.139 Laboratoire &Etude du MPtabolisme Azott!, INRA Theix-63I 10 Beaumont, France (Received 17 April 1978 - Accepted 4 January 1980) , on I. Growing rats were fed either ad lib. or with six (equal) meals offered every 4 h (from 10.00 hours). Rats 02 Oct 2021 at 01:32:10 of each group were killed at intervals of 4 h beginning at I 1.00 hours. Activities of cathepsin A (carboxy- peptidase A; EC3.4.1z.z), C (dipeptidyl peptidase; EC3.4.14.1) and D (endopeptidaseD EC3.4.23.5) were measured in liver and muscle homogenates and free amino acids in blood were determined. 2. In the rats fed ad lib. activities of carboxypeptidase A and endopeptidase D in liver and muscle showed significant variation, with maximum activity in the light period. In general, meal-feeding only caused minor differences in cathepsin activities; although significant differences occurred for carboxypeptidase A. For the latter enzyme a peak in activity occurred in the dark as well as in the light period. 3. Irrespective of the feeding schedule, the lower concentration of free essential amino acids of blood , subject to the Cambridge Core terms of use, available at occurred generally during the night period.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Soybean Bioactive Peptides and Their Functional Properties
    nutrients Review Soybean Bioactive Peptides and Their Functional Properties Cynthia Chatterjee 1,2, Stephen Gleddie 2 and Chao-Wu Xiao 1,3,* 1 Nutrition Research Division, Food Directorate, Health Products and Food Branch, Health Canada, Banting Research Centre, 251 Sir Frederick Banting Drive, Ottawa, ON K1A 0K9, Canada; [email protected] 2 Ottawa Research & Development Centre, Central Experimental Farm, Agriculture and Agri-Food Canada, 960 Carling Avenue Building#21, Ottawa, ON K1A 0C6, Canada; [email protected] 3 Food and Nutrition Science Program, Department of Chemistry, Carleton University, 1125 Colonel By Drive, Ottawa, ON K1S 5B6, Canada * Correspondence: [email protected]; Tel.: +1-613-558-7865; Fax: +1-613-948-8470 Received: 26 July 2018; Accepted: 29 August 2018; Published: 1 September 2018 Abstract: Soy consumption has been associated with many potential health benefits in reducing chronic diseases such as obesity, cardiovascular disease, insulin-resistance/type II diabetes, certain type of cancers, and immune disorders. These physiological functions have been attributed to soy proteins either as intact soy protein or more commonly as functional or bioactive peptides derived from soybean processing. These findings have led to the approval of a health claim in the USA regarding the ability of soy proteins in reducing the risk for coronary heart disease and the acceptance of a health claim in Canada that soy protein can help lower cholesterol levels. Using different approaches, many soy bioactive peptides that have a variety of physiological functions such as hypolipidemic, anti-hypertensive, and anti-cancer properties, and anti-inflammatory, antioxidant, and immunomodulatory effects have been identified.
    [Show full text]
  • CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders Chenyang Lu,*,† Mohammad A
    CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders Chenyang Lu,*,† Mohammad A. Amin,* and David A. Fox* CD13/aminopeptidase N is a widely expressed ectoen- and processing of inflammatory mediators, which are im- zyme with multiple functions. As an enzyme, CD13 portant features of immune responses. In this study, we regulates activities of numerous cytokines by cleaving review evidence concerning the involvement of CD13, includ- their N-terminals and is involved in Ag processing by ing a soluble form of the molecule in inflammation and its trimming the peptides bound to MHC class II. Inde- potential as a therapeutic target in inflammatory disorders. pendent of its enzymatic activity, cell membrane CD13 functions by cross-linking–induced signal transduc- Mechanisms of CD13 functions tion, regulation of receptor recycling, enhancement of CD13 was named aminopeptidase N because of its prefer- FcgR-mediated phagocytosis, and acting as a receptor ence for binding neutral amino acids and because it removes for cytokines. Moreover, soluble CD13 has multiple N-terminal amino acids from unsubstituted oligopeptides, proinflammatory roles mediated by binding to G-pro- with the exception of peptides with proline in the penulti- tein–coupled receptors. CD13 not only modulates de- mate position (11). By cleaving N termini, CD13 regulates velopment and activities of immune-related cells, but activity of numerous hormones,cytokines,andchemokines also regulates functions of inflammatory mediators. that participate in inflammation. Moreover, CD13 is coex- Therefore, CD13 is important in the pathogenesis of pressed by MHC class II (MHC II)–bearing APCs (12), and is various inflammatory disorders. Inhibitors of CD13 involved in the trimming of MHC II–associated peptides on the have shown impressive anti-inflammatory effects, but surface of APCs (5, 13, 14) (Fig.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110747 A1 Ramseier Et Al
    US 200601 10747A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110747 A1 Ramseier et al. (43) Pub. Date: May 25, 2006 (54) PROCESS FOR IMPROVED PROTEIN (60) Provisional application No. 60/591489, filed on Jul. EXPRESSION BY STRAIN ENGINEERING 26, 2004. (75) Inventors: Thomas M. Ramseier, Poway, CA Publication Classification (US); Hongfan Jin, San Diego, CA (51) Int. Cl. (US); Charles H. Squires, Poway, CA CI2O I/68 (2006.01) (US) GOIN 33/53 (2006.01) CI2N 15/74 (2006.01) Correspondence Address: (52) U.S. Cl. ................................ 435/6: 435/7.1; 435/471 KING & SPALDING LLP 118O PEACHTREE STREET (57) ABSTRACT ATLANTA, GA 30309 (US) This invention is a process for improving the production levels of recombinant proteins or peptides or improving the (73) Assignee: Dow Global Technologies Inc., Midland, level of active recombinant proteins or peptides expressed in MI (US) host cells. The invention is a process of comparing two genetic profiles of a cell that expresses a recombinant (21) Appl. No.: 11/189,375 protein and modifying the cell to change the expression of a gene product that is upregulated in response to the recom (22) Filed: Jul. 26, 2005 binant protein expression. The process can improve protein production or can improve protein quality, for example, by Related U.S. Application Data increasing solubility of a recombinant protein. Patent Application Publication May 25, 2006 Sheet 1 of 15 US 2006/0110747 A1 Figure 1 09 010909070£020\,0 10°0 Patent Application Publication May 25, 2006 Sheet 2 of 15 US 2006/0110747 A1 Figure 2 Ester sers Custer || || || || || HH-I-H 1 H4 s a cisiers TT closers | | | | | | Ya S T RXFO 1961.
    [Show full text]
  • The Microbiota-Produced N-Formyl Peptide Fmlf Promotes Obesity-Induced Glucose
    Page 1 of 230 Diabetes Title: The microbiota-produced N-formyl peptide fMLF promotes obesity-induced glucose intolerance Joshua Wollam1, Matthew Riopel1, Yong-Jiang Xu1,2, Andrew M. F. Johnson1, Jachelle M. Ofrecio1, Wei Ying1, Dalila El Ouarrat1, Luisa S. Chan3, Andrew W. Han3, Nadir A. Mahmood3, Caitlin N. Ryan3, Yun Sok Lee1, Jeramie D. Watrous1,2, Mahendra D. Chordia4, Dongfeng Pan4, Mohit Jain1,2, Jerrold M. Olefsky1 * Affiliations: 1 Division of Endocrinology & Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA. 2 Department of Pharmacology, University of California, San Diego, La Jolla, California, USA. 3 Second Genome, Inc., South San Francisco, California, USA. 4 Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA. * Correspondence to: 858-534-2230, [email protected] Word Count: 4749 Figures: 6 Supplemental Figures: 11 Supplemental Tables: 5 1 Diabetes Publish Ahead of Print, published online April 22, 2019 Diabetes Page 2 of 230 ABSTRACT The composition of the gastrointestinal (GI) microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose homeostasis remain to be defined. Here we show that blood and intestinal levels of the microbiota-produced N-formyl peptide, formyl-methionyl-leucyl-phenylalanine (fMLF), are elevated in high fat diet (HFD)- induced obese mice. Genetic or pharmacological inhibition of the N-formyl peptide receptor Fpr1 leads to increased insulin levels and improved glucose tolerance, dependent upon glucagon- like peptide-1 (GLP-1). Obese Fpr1-knockout (Fpr1-KO) mice also display an altered microbiome, exemplifying the dynamic relationship between host metabolism and microbiota.
    [Show full text]
  • Cloning of the Prolyl-Dipeptidyl-Peptidase from Aspergillus Oryzae
    Patentamt Europaisches ||| || 1 1| || || || || || || || || ||| || (19) J European Patent Office Office europeen des brevets (11) EP 0 897 012 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) int. CI.6: C12N 15/57, C12N 9/48, 17.02.1999 Bulletin 1999/07 C12N 1/15, C12N 1/19, (21) Application number: 97111377.4 C12P 21/06, A23J 3/30 (22) Date of filing: 05.07.1997 (84) Designated Contracting States: • Doumas, Agnes AT BE CH DE DK ES Fl FR GB GR IE IT LI LU MC 1124 Gollion (CH) NL PT SE • Affolter, Michael Designated Extension States: 1009 Pully (CH) AL LT LV RO SI • Van Den Broek Epalinges (CH) (71) Applicant: SOCIETE DES PRODUITS NESTLE S.A. (74) Representative: 1800 Vevey (CH) Straus, Alexander, Dr. Dipl.-Chem. et al KIRSCHNER & KURIG (72) Inventors: Patentanwalte • Monod, Michel Sollner Strasse 38 1 01 2 Lausanne (CH) 81 479 Munchen (DE) (54) Cloning of the prolyl-dipeptidyl-peptidase from aspergillus oryzae (57) The invention has for object the new recom- lysate obtainable by fermentation with at least a micro- binant prolyl-dipeptidyl-peptidase enzyme (DPP IV) oganism providing a prolyl-dipeptidyl-peptidase activity from Aspergillus oryzae comprising the amino-acid higher than 50 mU per ml when grown in a minimal sequence from amino acid 1 to amino acid 755 of SEQ medium containing 1 % (w/v) of wheat gluten. ID NO:2 or functional derivatives thereof, and providing a high level of hydrolysing specificity towards proteins and peptides starting with X-Pro- thus liberating dipep- tides of X-Pro type, wherein X is any amino-acid.
    [Show full text]
  • Partial Characterisation of Dipeptidyl Peptidase 4 (DP 4
    Partial Characterisation of Dipeptidyl Peptidase 4 (DP 4) for the Treatment of Type 2 Diabetes and its Identification as a novel Pharmaceutical Target for Stress-related Indications Beiträge zur Charakterisierung der Dipeptidylpeptidase 4 (DP 4) für die Behandlung von Typ-2-Diabetes und deren Identifizierung als ein neuartiges pharmazeutisches Ziel für stressvermittelte Indikationen Der Naturwissenschaftlichen Fakultät der Friedrich-Alexander-Universität Erlangen-Nürnberg zur Erlangung des Doktorgrades Dr. rer. nat. vorgelegt von M. Sc. (Biochemie) Leona Wagner aus Rheinfelden (Baden) Als Dissertation genehmigt von der Naturwissenschaftlichen Fakultät der Friedrich-Alexander-Universität Erlangen-Nürnberg Tag der mündlichen Prüfung: 23.10.2012 Vorsitzender der Promotionskommission: Prof. Dr. Rainer Fink Erstberichterstatter: Prof. Dr. med. Stephan von Hörsten Zweitberichterstatter: Prof. Dr. Johann Helmut Brandstätter Publications, Presentations and Posters Part of the present study have been published or submitted in the following journals or presented on the following conferences: Publications: 1. Hinke, S.A., McIntosh, C.H., Hoffmann, T., Kuhn-Wache, K., Wagner, L., Bar, J., Manhart, S., Wermann, M., Pederson, R.A., and Demuth, H.U. (2002) On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors. Diabetes Care 25, 1490- 1491. 2. Bär, J., Weber, A., Hoffmann, T., Stork, J., Wermann, M., Wagner, L., Aust, S., Gerhartz, B., and Demuth, H.U. (2003) Characterisation of human dipeptidyl peptidase IV expressed in Pichia pastoris. A structural and mechanistic comparison between the recombinant human and the purified porcine enzyme. Biol. Chem. 384, 1553-1563. 3. Engel, M., Hoffmann, T., Wagner, L., Wermann, M., Heiser, U., Kiefersauer, R., Huber, R., Bode, W., Demuth, H.U., and Brandstetter, H.
    [Show full text]
  • The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis
    REVIEW published: 07 August 2015 doi: 10.3389/fimmu.2015.00387 The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis Yannick Waumans, Lesley Baerts, Kaat Kehoe, Anne-Marie Lambeir and Ingrid De Meester* Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium Edited by: Research from over the past 20 years has implicated dipeptidyl peptidase (DPP) IV and Heidi Noels, its family members in many processes and different pathologies of the immune system. RWTH Aachen University, Germany Jürgen Bernhagen, Most research has been focused on either DPPIV or just a few of its family members. It is, RWTH Aachen University, Germany however, essential to consider the entire DPP family when discussing any one of its mem- Reviewed by: bers. There is a substantial overlap between family members in their substrate specificity, Rafael Franco, University of Barcelona, Spain inhibitors, and functions. In this review, we provide a comprehensive discussion on the Catherine Anne Abbott, role of prolyl-specific peptidases DPPIV, FAP, DPP8, DPP9, dipeptidyl peptidase II, prolyl Flinders University, Australia carboxypeptidase, and prolyl oligopeptidase in the immune system and its diseases. We Mark Gorrell, University of Sydney, Australia highlight possible therapeutic targets for the prevention and treatment of atherosclerosis, *Correspondence: a condition that lies at the frontier between inflammation
    [Show full text]
  • Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
    Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48
    [Show full text]
  • Biochemical Investigation of the Ubiquitin Carboxyl-Terminal Hydrolase Family" (2015)
    Purdue University Purdue e-Pubs Open Access Dissertations Theses and Dissertations Spring 2015 Biochemical investigation of the ubiquitin carboxyl- terminal hydrolase family Joseph Rashon Chaney Purdue University Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations Part of the Biochemistry Commons, Biophysics Commons, and the Molecular Biology Commons Recommended Citation Chaney, Joseph Rashon, "Biochemical investigation of the ubiquitin carboxyl-terminal hydrolase family" (2015). Open Access Dissertations. 430. https://docs.lib.purdue.edu/open_access_dissertations/430 This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact [email protected] for additional information. *UDGXDWH6FKRRO)RUP 8SGDWHG PURDUE UNIVERSITY GRADUATE SCHOOL Thesis/Dissertation Acceptance 7KLVLVWRFHUWLI\WKDWWKHWKHVLVGLVVHUWDWLRQSUHSDUHG %\ Joseph Rashon Chaney (QWLWOHG BIOCHEMICAL INVESTIGATION OF THE UBIQUITIN CARBOXYL-TERMINAL HYDROLASE FAMILY Doctor of Philosophy )RUWKHGHJUHHRI ,VDSSURYHGE\WKHILQDOH[DPLQLQJFRPPLWWHH Chittaranjan Das Angeline Lyon Christine A. Hrycyna George M. Bodner To the best of my knowledge and as understood by the student in the Thesis/Dissertation Agreement, Publication Delay, and Certification/Disclaimer (Graduate School Form 32), this thesis/dissertation adheres to the provisions of Purdue University’s “Policy on Integrity in Research” and the use of copyrighted material. Chittaranjan Das $SSURYHGE\0DMRU3URIHVVRU V BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB $SSURYHGE\R. E. Wild 04/24/2015 +HDGRIWKH'HSDUWPHQW*UDGXDWH3URJUDP 'DWH BIOCHEMICAL INVESTIGATION OF THE UBIQUITIN CARBOXYL-TERMINAL HYDROLASE FAMILY Dissertation Submitted to the Faculty of Purdue University by Joseph Rashon Chaney In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy May 2015 Purdue University West Lafayette, Indiana ii All of this I dedicate wife, Millicent, to my faithful and beautiful children, Josh and Caleb.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel Et Al
    USOO8561811 B2 (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel et al. (45) Date of Patent: Oct. 22, 2013 (54) SUBSTRATE FOR IMMOBILIZING (56) References Cited FUNCTIONAL SUBSTANCES AND METHOD FOR PREPARING THE SAME U.S. PATENT DOCUMENTS 3,952,053 A 4, 1976 Brown, Jr. et al. (71) Applicants: Christian Gert Bluchel, Singapore 4.415,663 A 1 1/1983 Symon et al. (SG); Yanmei Wang, Singapore (SG) 4,576,928 A 3, 1986 Tani et al. 4.915,839 A 4, 1990 Marinaccio et al. (72) Inventors: Christian Gert Bluchel, Singapore 6,946,527 B2 9, 2005 Lemke et al. (SG); Yanmei Wang, Singapore (SG) FOREIGN PATENT DOCUMENTS (73) Assignee: Temasek Polytechnic, Singapore (SG) CN 101596422 A 12/2009 JP 2253813 A 10, 1990 (*) Notice: Subject to any disclaimer, the term of this JP 2258006 A 10, 1990 patent is extended or adjusted under 35 WO O2O2585 A2 1, 2002 U.S.C. 154(b) by 0 days. OTHER PUBLICATIONS (21) Appl. No.: 13/837,254 Inaternational Search Report for PCT/SG2011/000069 mailing date (22) Filed: Mar 15, 2013 of Apr. 12, 2011. Suen, Shing-Yi, et al. “Comparison of Ligand Density and Protein (65) Prior Publication Data Adsorption on Dye Affinity Membranes Using Difference Spacer Arms'. Separation Science and Technology, 35:1 (2000), pp. 69-87. US 2013/0210111A1 Aug. 15, 2013 Related U.S. Application Data Primary Examiner — Chester Barry (62) Division of application No. 13/580,055, filed as (74) Attorney, Agent, or Firm — Cantor Colburn LLP application No.
    [Show full text]